Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of metabolic marker in renal clear cell carcinoma

A technology for renal clear cell carcinoma and metabolites, which is applied in the application field of metabolic markers in renal clear cell carcinoma, can solve the problems of insufficient accuracy of early diagnosis and achieve the effect of improving the quality of life

Inactive Publication Date: 2019-09-27
PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, imaging techniques such as ultrasound, nuclear magnetic resonance, and dynamic enhanced CT are commonly used clinically for the diagnosis of renal cell carcinoma. Although the diagnostic level of renal cell carcinoma has been greatly improved, the accuracy of early diagnosis is still insufficient.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of metabolic marker in renal clear cell carcinoma
  • Application of metabolic marker in renal clear cell carcinoma
  • Application of metabolic marker in renal clear cell carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Screening of Metabolites Related to Renal Clear Cell Carcinoma

[0037] 1. Materials and reagents

[0038] 1) Instruments: Waters H-class liquid chromatograph (waters company); LTQ-Orbitrap velos pro mass spectrometer (Thermofisher Scientific company).

[0039] 2) Main reagents: acetonitrile (Thermofisher Scientific Company); C18 reverse-phase chromatographic column (3.0 mm×100 mm, C18, 1.7 μm, Waters Company).

[0040] 3) Samples: urine from 67 patients with clear cell renal cell carcinoma and 96 age- and gender-matched normal controls from Peking Union Medical College Hospital.

[0041] 2. Experimental method

[0042] 2.1 Sample collection

[0043] Collect fasting morning urine and centrifuge at 5000g for 30min to remove sediment.

[0044] 2.2 Extraction of metabolites

[0045] Take 200μl urine supernatant, add 200μl acetonitrile, vortex, let stand at 4°C for 30min, centrifuge at 14000g for 10min, take the supernatant, concentrate by centrifugation, red...

Embodiment 2

[0057] Example 2 Diagnosis of patients with renal clear cell carcinoma

[0058] 1. Sample collection

[0059] Urine was collected from 33 cases of clear renal cell carcinoma and 33 normal persons.

[0060] 2. Concrete steps of extraction of metabolites Simultaneous Example 1

[0061] 3. Detection and analysis of metabolites by liquid chromatography-high resolution mass spectrometry

[0062] The detection procedure is the same as in Example 1, and the prediction effect of the nine metabolites in Table 1 on clear renal cell carcinoma is evaluated by using the ROC curve. The results show that the AUC value of the joint prediction is 0.885, which can be accurately predicted from 33 clear renal cell carcinoma samples 26 cases ( Figure 4 ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a metabolic marker in renal clear cell carcinoma. According to the invention, metabonomics analysis is carried out by collecting renal clear cell carcinoma and urine samples of normal people, and metabolites with significant differences in different groups are found, so that early renal clear cell carcinoma can be predicted by using the metabolites, and then personalized treatment of patients is realized.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the application of metabolic markers in renal clear cell carcinoma. Background technique [0002] Renal carcinoma is a malignant tumor originating from the urothelial system of the renal parenchyma, including various subtypes of renal cell carcinoma originating from different parts of the urinary tubule. Renal cancer accounts for 80% to 90% of renal malignancies. Among the urological tumors in our country, the incidence of kidney cancer is second only to bladder cancer. Worldwide, the incidence of renal cell carcinoma in developed countries is higher than that in developing countries (A. Znaor, J. Lortet-Tieulent, M. Laversanne, A. Jemal, F. Bray, International variations and trends in renal cell carcinoma incidence and Mortality, European urology, 67(2015) 519-530). Renal cancer can be divided into clear cell renal cell carcinoma (ccRCC, 70%-85%), papillary renal cell carcinoma (pRCC,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574G01N30/89G01N30/72G01N30/88G01N30/86G01N30/74G01N30/62
CPCG01N33/57407G01N33/57488G01N33/57496G01N33/57484G01N30/89G01N30/72G01N30/88G01N30/8634G01N30/74G01N30/62G01N2030/8813G01N2570/00G01N2560/00
Inventor 张玉石王站孙伟刘晓燕
Owner PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products